bell potter benefiting from the hepc gold rush, page-8

The scope of the report surprised me....you don't tend to get that type of coverage for a $30mil spec in any sector.With that type of detail it looks to be aimed at the more sophisticated investor.I imagine it would have had some Biotron involvement.

There is more than just a passing interest here and they seemed to want this report out in a hurry(may have something to do with this weeks conference in Spain).

I have it as HIV phaselb/lla results out mid 2012(page 24)

Not surprisingly many of the researchers opinions are in line with what has been posted here over the past few months.GL Holders